CTRI/2014/10/005139
Completed
Phase 4
Comparative efficacy of metformin, pioglitazone and rosuvastatin on metabolic profile in patients with metabolic syndrome.
Overview
- Phase
- Phase 4
- Intervention
- Not specified
- Conditions
- Health Condition 1: null- Metabolic Syndrome
- Sponsor
- Department of Pharmacology
- Enrollment
- 140
- Status
- Completed
- Last Updated
- 4 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •Patients with 18\-60 years of age and either sex diagnosed with Metabolic Syndrome. Conformation to written informed consent.
Exclusion Criteria
- •Patient not willing to give informed consent, type I diabetes mellitus, type II diabetes mellitus(fasting plasma glucose of \>126mg/dl), severely deranged lipid profile(TG \>500 mg/dl, LDLC \>250mg /dl), liver enzymes \>2 times of upper limit and serum creatinine \>2mg/dl, history of heart disease, familial dyslipidemia, hyper or
- •hypothyroidism, major medical/surgical illness, hypersensitivity to any of the used drugs, pregnant and lactating females, patient on any other long term concomitant drugs known to affect
- •glucose tolerance or lipid profile
Outcomes
Primary Outcomes
Not specified
Similar Trials
Completed
Not Applicable
Comparative Efficacy of Pioglitazone and Metformin in Glucose Variability in Type 2 Diabetestype 2 diabetesJPRN-UMIN000001891Jikei University School of Medicine20
Completed
Phase 3
The comparison of metformin, pioglitazon and Silymarin on biochemical indicesIRCT201105084849N2Vice-Cancellor for Research of Qazvin University of Medical Science66
Active, not recruiting
Not Applicable
Impact of Pioglitazone, Metformin and the combination of both on cardiovascular risk in insulin-treated patients with Type 2 diabetes – The PIOcomb Study - PIOcomb StudyEUCTR2007-006706-14-ATTakeda Pharma GmbH200
Active, not recruiting
Not Applicable
Impact of Pioglitazone, Metformin and the combination of both on cardiovascular risk in insulin-treated patients with Type 2 diabetes – The PIOcomb Study - PIOcomb StudyDiabetes mellitus type 2MedDRA version: 9.1Level: LLTClassification code 10045242Term: Type II diabetes mellitusEUCTR2007-006706-14-DETakeda Pharma GmbH
Completed
Not Applicable
Differential effects of metformin and pioglithazone on hs-CRP in patients with type II DM.diabetes mellitus II.non-insulin-dependent diabetes mellitusIRCT201109067482N1Qazvin University of Medical Sciences40